
Cystic fibrosis Program in Pharmaceutical Benefits Scheme (PBS) 012-18051113

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines the PBS subsidies for ivacaftor,
lumacaftor+ivacaftor, tezacaftor+ivacaftor and
elexacaftor+tezacaftor+ivacaftor for patients with cystic fibrosis (CF).

Cystic fibrosis and listing dates

Cystic fibrosis is a condition that affects the cells that produce
mucus, sweat and digestive juices. It causes these fluids to become
thick and sticky. They then plug up tubes, ducts and passageways leading
to airway and digestive issues.

Listing dates:

-   ivacaftor - 1 December 2014
-   lumacaftor+ivacaftor - 1 October 2018
-   tezacaftor+ivacaftor - 1 December 2019
-   elexacaftor+tezacaftor+ivacaftor - 1 April 2022

See Written Authority Required Drugs for more information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS - Complex
Drugs Programs team and choose the option relevant to the condition
treated.

The Resources page contains links to application forms, calculation
sheets, contact details, restriction and item codes, and the PBS and the
Services Australia websites.

Related links

Written Authority Required Drugs

Processing Written Authority Required Listings

Processing written authority approval requests

Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA
System)

                                   

-   Services Australia ABN 90 794 605 008 
